Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (601-610 of 724) with videos related to

Pageof 73
Sort By:
American Journal of Otolaryngology|June 25, 2021
A closer look at 30 day hospital readmissions after head and neck cancer surgeryR Puccia, A Ramamurthi, S E Grond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerA J Armstrong, M Häggman, W M Stadler, et al.
Cancer|February 2, 2019
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2James K Godfrey, Chadi Nabhan, Theodore Karrison, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
BJU International|November 22, 2014
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trialFriedrich-Carl von Rundstedt, Douglas A Mata, Susan Groshen, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Investigational New Drugs|May 10, 2011
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II ConsortiumManish R Sharma, Kristen Wroblewski, Blase N Polite, et al.
Cancer|February 26, 2004
Gene expression profiling of renal medullary carcinoma: potential clinical relevanceXiming J Yang, Jun Sugimura, Maria S Tretiakova, et al.
Pageof 73

Showing results (601-610 of 724) with videos related to

Sort By:
Pageof 73
American Journal of Otolaryngology|June 25, 2021
A closer look at 30 day hospital readmissions after head and neck cancer surgeryR Puccia, A Ramamurthi, S E Grond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerA J Armstrong, M Häggman, W M Stadler, et al.
Cancer|February 2, 2019
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2James K Godfrey, Chadi Nabhan, Theodore Karrison, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
BJU International|November 22, 2014
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trialFriedrich-Carl von Rundstedt, Douglas A Mata, Susan Groshen, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Investigational New Drugs|May 10, 2011
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II ConsortiumManish R Sharma, Kristen Wroblewski, Blase N Polite, et al.
Cancer|February 26, 2004
Gene expression profiling of renal medullary carcinoma: potential clinical relevanceXiming J Yang, Jun Sugimura, Maria S Tretiakova, et al.
Pageof 73